These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1198 related articles for article (PubMed ID: 12548325)
1. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Berman B; Poochareon VN; Villa AM Skin Therapy Lett; 2002 Nov; 7(9):1-6. PubMed ID: 12548325 [TBL] [Abstract][Full Text] [Related]
2. Current and potential uses of imiquimod. Chang YC; Madkan V; Cook-Norris R; Sra K; Tyring S South Med J; 2005 Sep; 98(9):914-20. PubMed ID: 16217984 [TBL] [Abstract][Full Text] [Related]
3. Imiquimod: a review. Gupta AK; Browne M; Bluhm R J Cutan Med Surg; 2002; 6(6):554-60. PubMed ID: 12362256 [TBL] [Abstract][Full Text] [Related]
4. Imiquimod as an immune response modulator in infectious conditions. Skinner RB Postgrad Med; 2002 Dec; 112(6 Suppl Using):8-16. PubMed ID: 19667608 [TBL] [Abstract][Full Text] [Related]
5. Imiquimod in dermatology: an overview. Hanna E; Abadi R; Abbas O Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases. Erbagci Z; Tuncel AA; Erbagci I J Drugs Dermatol; 2006; 5(7):668-71. PubMed ID: 16865875 [TBL] [Abstract][Full Text] [Related]
7. Imiquimod 5% cream use in dermatology, side effects and recent patents. Cantisani C; Lazic T; Richetta AG; Clerico R; Mattozzi C; Calvieri S Recent Pat Inflamm Allergy Drug Discov; 2012 Jan; 6(1):65-9. PubMed ID: 22185454 [TBL] [Abstract][Full Text] [Related]
8. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children. Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935 [TBL] [Abstract][Full Text] [Related]
9. Viral and nonviral uses of imiquimod: a review. Gupta AK; Cherman AM; Tyring SK J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314 [TBL] [Abstract][Full Text] [Related]
11. Imiquimod; an international update on therapeutic uses in dermatology. Tyring S; Conant M; Marini M; Van Der Meijden W; Washenik K Int J Dermatol; 2002 Nov; 41(11):810-6. PubMed ID: 12453012 [TBL] [Abstract][Full Text] [Related]
13. Topical imiquimod: mechanism of action and clinical applications. Vidal D Mini Rev Med Chem; 2006 May; 6(5):499-503. PubMed ID: 16719822 [TBL] [Abstract][Full Text] [Related]
14. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273 [TBL] [Abstract][Full Text] [Related]
15. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. Persaud AN; Shamuelova E; Sherer D; Lou W; Singer G; Cervera C; Lamba S; Lebwohl MG J Am Acad Dermatol; 2002 Oct; 47(4):553-6. PubMed ID: 12271300 [TBL] [Abstract][Full Text] [Related]
17. Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology. Berman B Int J Dermatol; 2002 May; 41 Suppl 1():7-11. PubMed ID: 12087816 [No Abstract] [Full Text] [Related]
18. A review of the applications of imiquimod: a novel immune response modifier. Syed TA Expert Opin Pharmacother; 2001 May; 2(5):877-82. PubMed ID: 12219723 [TBL] [Abstract][Full Text] [Related]
19. Successful treatment of perianal warts in a child with 5% imiquimod cream. Gruber PC; Wilkinson J J Dermatolog Treat; 2001 Dec; 12(4):215-7. PubMed ID: 12241631 [TBL] [Abstract][Full Text] [Related]